» Articles » PMID: 10201923

Human T Cells Express the C5a Receptor and Are Chemoattracted to C5a

Overview
Journal J Immunol
Date 1999 Apr 14
PMID 10201923
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

The anaphylatoxin C5a is a potent mediator of inflammation that exerts a broad range of activity on cells of the myeloid lineage. In this study, we present the first evidence that human T cells express the C5a receptor (C5aR) and are chemotactic to C5a. Using FACS analysis, we found that the C5aR was expressed at a low basal level on unstimulated T cells and was strikingly up-regulated upon PHA stimulation in a time- and dose-dependent manner. CD3+ sorted T cells as well as Jurkat T cells were shown to express C5aR mRNA as assessed by RT-PCR. Moreover, semiquantitative RT-PCR analysis demonstrated that C5aR mRNA was down-regulated in purified T cells upon long-term PHA stimulation. To demonstrate that C5a was biologically active on T cells, we investigated the chemotactic activity of C5a and observed that purified CD3+ T cells are chemotactic to C5a at nanomolar concentrations. Finally, using a combination of in situ hybridization and immunohistochemistry, we showed that the T cells infiltrating the central nervous system during experimental allergic encephalomyelitis express the C5aR mRNA. In summary, these results suggest that C5a exerts direct effects on T cells and could be involved in the trafficking of T cells under physiological and pathological conditions, including inflammatory diseases of the central nervous system.

Citing Articles

Complement System and Adhesion Molecule Skirmishes in Fabry Disease: Insights into Pathogenesis and Disease Mechanisms.

Magnusen A, Pandey M Int J Mol Sci. 2024; 25(22).

PMID: 39596318 PMC: 11594573. DOI: 10.3390/ijms252212252.


Complement protein C3a enhances adaptive immune responses towards FVIII products.

Ringler E, Ortega Iannazzo S, Herzig J, Weiss L, Anzaghe M, Miller L Haematologica. 2023; 108(6):1579-1589.

PMID: 36727395 PMC: 10230409. DOI: 10.3324/haematol.2022.281762.


Complement-targeted therapies in kidney transplantation-insights from preclinical studies.

Anwar I, DeLaura I, Ladowski J, Gao Q, Knechtle S, Kwun J Front Immunol. 2022; 13:984090.

PMID: 36311730 PMC: 9606228. DOI: 10.3389/fimmu.2022.984090.


Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.

Kozma G, Meszaros T, Bakos T, Hennies M, Bencze D, Uzonyi B Front Immunol. 2021; 12:642860.

PMID: 33995361 PMC: 8113956. DOI: 10.3389/fimmu.2021.642860.


Complement in Tumourigenesis and the Response to Cancer Therapy.

OBrien R, Cannon A, Reynolds J, Lysaght J, Lynam-Lennon N Cancers (Basel). 2021; 13(6).

PMID: 33802004 PMC: 7998562. DOI: 10.3390/cancers13061209.